Farallon Capital Management’s Larimar Therapeutics LRMR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-150,697
| Closed | -$2.01M | – | 107 |
|
|
2019
Q4 | $2.01M | Hold |
150,697
| – | – | 0.01% | 110 |
|
|
2019
Q3 | $1.34M | Buy |
150,697
+697
| +0.5% | +$6.18K | 0.01% | 96 |
|
|
2019
Q2 | $2.14M | Hold |
150,000
| – | – | 0.01% | 99 |
|
|
2019
Q1 | $4.93M | Buy |
150,000
+2,083
| +1% | +$68.5K | 0.04% | 85 |
|
|
2018
Q4 | $8.79M | Buy |
147,917
+12,500
| +9% | +$742K | 0.06% | 80 |
|
|
2018
Q3 | $19M | Buy |
135,417
+29,872
| +28% | +$4.19M | 0.11% | 68 |
|
|
2018
Q2 | $13M | Buy |
+105,545
| New | +$13M | 0.08% | 70 |
|
|
2016
Q3 | – | Sell |
-69,900
| Closed | -$5.02M | – | 67 |
|
|
2016
Q2 | $5.02M | Hold |
69,900
| – | – | 0.07% | 53 |
|
|
2016
Q1 | $5.6M | Buy |
69,900
+15,000
| +27% | +$1.2M | 0.05% | 63 |
|
|
2015
Q4 | $4.14M | Buy |
54,900
+35,625
| +185% | +$2.69M | 0.04% | 57 |
|
|
2015
Q3 | $7.39M | Buy |
19,275
+108
| +0.6% | +$41.4K | 0.1% | 63 |
|
|
2015
Q2 | $7.97M | Buy |
19,167
+8,334
| +77% | +$3.46M | 0.11% | 70 |
|
|
2015
Q1 | $5.15M | Buy |
10,833
+5,833
| +117% | +$2.77M | 0.08% | 78 |
|
|
2014
Q4 | $1.85M | Hold |
5,000
| – | – | 0.03% | 76 |
|
|
2014
Q3 | $1.18M | Buy |
+5,000
| New | +$1.18M | 0.02% | 77 |
|